1 - 5 of 5 results
0.6 CME CREDIT

This activity will provide an evidence-based approach to diagnosing irritable bowel syndrome (IBS) with minimal testing. Diagnostic tests that facilitate a positive diagnosis of IBS and effective approaches for educating patients will be highlighted. The panel will spotlight diet changes and over-the-counter agents which are helpful first-line therapies. Evidence-based guidelines will identify the most effective and best tolerated prescription agents for IBS and chronic constipation patients.


1 CME CREDIT

Increasing numbers of patients are talking with their health care professionals about specialized diets and testing for allergies and food sensitivities as part of their overall wellness plan. Good diet quality is a well-recognized element of lifestyle medicine, but there is growing confusion among medical professionals and consumers about "good" foods and if they should eliminate certain foods from their diet. This talk will cover several of the popular media approaches to healthy living, including diets like Gluten Free, Whole 30, Ketogenic, as well as relevant data for health-related outcomes for each. The differences between allergic bowel disorders and intolerances will be discussed. Clinical and nutritional counseling tips will be provided.


1 CME CREDIT

Irritable bowel syndrome (IBS) is the most common disorder seen and treated by gastroenterologists. Despite this, many physicians have difficulty making a definitive diagnosis and approximately 75% of the general population with IBS symptoms remains undiagnosed. Part of this stems from the fact that there are currently no diagnostic studies which conclusively confirm IBS. As such, it has been and continues to be considered a diagnosis of exclusion when in reality newer diagnostic criteria and minimal diagnostic testing can lead to a diagnosis with 98-99% accuracy. A better understanding of the underlying pathophysiology of this disorder has also let to more accurate treatment strategies. In this discussion we will dispel many of the myths and misconceptions surrounding this syndrome.


0.75 CME CREDIT

Irritable bowel syndrome (IBS) is the most common disorder seen and treated by gastroenterologists. Despite this, many physicians have difficulty making a definitive diagnosis and approximately 75% of the general population with IBS symptoms remains undiagnosed. Part of this stems from the fact that there are currently no diagnostic studies which conclusively confirm IBS. As such, it has been and continues to be considered a diagnosis of exclusion when in reality newer diagnostic criteria and minimal diagnostic testing can lead to a diagnosis with 98-99% accuracy. A better understanding of the underlying pathophysiology of this disorder has also let to more accurate treatment strategies. In this discussion we will dispel many of the myths and misconceptions surrounding this syndrome.


0.75 CME CREDIT

The faculty will provide an overview and update of irritable bowel syndrome (IBS), including the new Rome IV diagnostic criteria, pathophysiology and pharmacologic and non-pharmacologic treatment approaches. The lecture will review the new Rome multidimensional clinical disease profiles (MDCP), which helps to characterize the unique profile of a FGID patient with a classification of diagnosis, clinical modifiers, psychological symptoms, quality of life, and biomarkers that help to guide treatment.